Tetrous, Inc.

Tetrous, Inc. is a pioneering company in regenerative medicine, focusing on innovative surgical solutions for tendon-to-bone repairs, particularly within sports medicine applications. Tetrous, Inc. specializes in regenerative medicine and was founded in 2019 in Los Angeles, US.

The company has completed 1 deal and raised a total of USD 6. 5 mn through its Series A funding round on March 10, 2025. The founder's background information is not disclosed. Tetrous, Inc.

specializes in regenerative medicine, focusing primarily on innovative solutions for tendon-to-bone repairs, particularly in sports medicine applications. Their flagship product, EnFix®, is engineered to address Enthesis Failure Syndrome by promoting the remodeling of tissue that closely resembles the natural bone-tendon enthesis. The EnFix family of products includes EnFix RC™, which is specifically developed for rotator cuff repairs and has been utilized in numerous surgical procedures. The underlying technology, including Bone Textile™ and FormLok™, enhances the biological performance of the materials, resulting in better integration during surgical interventions.

The company’s products target healthcare providers, particularly orthopedic surgeons and sports medicine specialists, serving markets in the United States and various international regions where advanced orthopedic solutions are in demand. Tetrous, Inc. generates revenue through the sale of its specialized surgical products directly to hospitals and surgical centers, primarily focusing on the orthopedic and sports medicine sectors. The transactions typically involve direct sales agreements with healthcare facilities, where the EnFix® products are utilized in surgical procedures aimed at repairing rotator cuff injuries and other tendon-to-bone issues.

Revenue is driven by the volume of procedures performed using their products, with sales structured around one-time purchases rather than subscriptions or ongoing service contracts. The company's innovative products, such as EnFix RC™, are positioned at the forefront of the orthopedic market, catering to a growing need for effective and reliable solutions in tendon healing. In March 2025, Tetrous, Inc. raised USD 6.

5 mn in Series A funding from unspecified investors. The company will use the funding to expand market penetration, develop clinical data on patient outcomes, and broaden the surgical applications of its technology for hip, knee, ankle, and elbow procedures. Plans for future growth include upcoming new products designed to enhance surgical outcomes and entering new markets to increase their reach globally.